TD Asset Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-188,844
| Closed | -$8.97M | – | 1235 |
|
|
2025
Q3 | $8.97M | Sell |
188,844
-2,604
| -1% | -$126K | 0.01% | 682 |
|
|
2025
Q2 | $10.2M | Sell |
191,448
-17,400
| -8% | -$791K | 0.01% | 633 |
|
|
2025
Q1 | $8.45M | Buy |
208,848
+39,194
| +23% | +$1.66M | 0.01% | 679 |
|
|
2024
Q4 | $4.72M | Buy |
169,654
+46,200
| +37% | +$1.4M | ﹤0.01% | 805 |
|
|
2024
Q3 | $3.49M | Sell |
123,454
-31,138
| -20% | -$812K | ﹤0.01% | 874 |
|
|
2024
Q2 | $3.63M | Buy |
154,592
+29,600
| +24% | +$633K | ﹤0.01% | 840 |
|
|
2024
Q1 | $3.16M | Buy |
124,992
+30,790
| +33% | +$740K | ﹤0.01% | 887 |
|
|
2023
Q4 | $2.2M | Sell |
94,202
-31,890
| -25% | -$629K | ﹤0.01% | 973 |
|
|
2023
Q3 | $6.38M | Buy |
126,092
+63,346
| +101% | +$2.95M | 0.01% | 671 |
|
|
2023
Q2 | $2.93M | Buy |
62,746
+4,724
| +8% | +$216K | ﹤0.01% | 860 |
|
|
2023
Q1 | $2.22M | Buy |
58,022
+5,600
| +11% | +$250K | ﹤0.01% | 950 |
|
|
2022
Q4 | $2.87M | Buy |
52,422
+33,300
| +174% | +$1.43M | ﹤0.01% | 886 |
|
|
2022
Q3 | $570K | Buy |
+19,122
| New | +$293K | ﹤0.01% | 1271 |
|
|
2022
Q1 | – | Sell |
-25,102
| Closed | -$531K | – | 1484 |
|
|
2021
Q4 | $531K | Hold |
25,102
| – | – | ﹤0.01% | 1372 |
|
|
2021
Q3 | $561K | Hold |
25,102
| – | – | ﹤0.01% | 1366 |
|
|
2021
Q2 | $538K | Hold |
25,102
| – | – | ﹤0.01% | 1374 |
|
|
2021
Q1 | $728K | Buy |
25,102
+5,497
| +28% | +$166K | ﹤0.01% | 1321 |
|
|
2020
Q4 | $506K | Buy |
19,605
+4,000
| +26% | +$111K | ﹤0.01% | 1332 |
|
|
2020
Q3 | $480K | Buy |
15,605
+6,883
| +79% | +$241K | ﹤0.01% | 1250 |
|
|
2020
Q2 | $217K | Buy |
+8,722
| New | +$199K | ﹤0.01% | 1286 |
|
|
2020
Q1 | – | Sell |
-10,322
| Closed | -$229K | – | 1366 |
|
|
2019
Q4 | $229K | Hold |
10,322
| – | – | ﹤0.01% | 1354 |
|
|
2019
Q3 | $235K | Buy |
+10,322
| New | +$240K | ﹤0.01% | 1287 |
|
Other funds holding AKRO
TD Asset Management's AKRO Position: Q4 2025 in Review
TD Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 188,844 shares — an estimated $8.97M sold.
TD Asset Management first reported a position in AKRO in Q3 2019 and held it in 22 quarters. The position peaked at $10.2M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- TD Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- TD Asset Management sold 188,844 Akero Therapeutics shares in Q4 2025, an estimated $8.97M.
- TD Asset Management first reported a position in Akero Therapeutics in Q3 2019 and held it in 22 quarters.
- TD Asset Management's Akero Therapeutics position peaked at $10.2M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on TD Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.